Metabolic disorder and intestinal microflora dysbiosis in chronic inflammatory demyelinating polyradiculoneuropathy

Study information

Needs review

study design

cross-sectional observational, not case-control
laboratory experiment

Citation

PMID PubMed identifier for scientific articles.

36627678

DOI Digital object identifier for electronic documents.

10.1186/s13578-023-00956-1

URI

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832664

Authors

Fu J, Shan J, Cui Y, Yan C, Wang Q, Han J, Cao G

Journal

Cell & bioscience

Year

2023

Keywords:

Arachidonic acid, Bile acids, Chronic inflammatory demyelinating polyradiculoneuropathy, Gut microbial dysbiosis, Metabolic disorder

OBJECTIVE: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare acquired immune-mediated neuropathy. Although microbial infection is potentially a contributing factor, a causative link between CIDP and microbial infection remains unclear. There is also no definitive biomarker for CIDP diagnostics and therapies. The present study aimed to characterize the serum metabolic profile and gut microbiome structure in CIDP. METHODS: Targeted metabolomics profiling of serum, using liquid chromatography-mass spectrometry, and metagenomics sequencing of stool samples from a cohort of CIDP and non-CIDP subjects were performed to evaluate serum metabolic profiles and gut microbiome structure in CIDP subjects relative to healthy controls. RESULTS: Metabolome data revealed that the bile acids profile was perturbed in CIDP with bile acids and arachidonic acid enriched significantly in CIDP versus non-CIDP controls. Metagenome data revealed that opportunistic pathogens, such as Klebsiella pneumonia and Megamonas funiformis, and genes involved in bacterial infection were notably more abundant in CIDP subjects, while gut microbes related to biotransformation of secondary bile acids were abnormal in CIDP versus non-CIDP subjects. Correlation analysis revealed that changes in secondary bile acids were associated with altered gut microbes, including Bacteroides ovatus, Bacteroides caccae, and Ruminococcus gnavus. CONCLUSION: Bile acids and arachidonic acid metabolism were disturbed in CIDP subjects and might be affected by the dysbiosis of gut microbial flora. These findings suggest that the combination of bile acids and arachidonic acid could be used as a CIDP biomarker and that modulation of gut microbiota might impact the clinical course of CIDP.

Experiment 1

Edit History Delete

Mark reviewed

Your review change was submittedDuplicate this Experiment Add a new Signature

Needs review

Curated date: 2024/03/12

Curator: Zheeburg

Revision editor(s): Zheeburg

Subjects

Location of subjects: United States of America

Host species Species from which microbiome was sampled. Contact us to have more species added.: Homo sapiens

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology: Colon , Large intestine Hindgut,Large bowel,Posterior intestine,Colon,colon,Intestinum crassum,Large intestine,large intestine

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology: Chronic inflammatory demyelinating polyradiculoneuropathy chronic inflammatory demyelinating polyradiculoneuropathy,chronic inflammatory demyelinating polyradiculoneuropathy (disorder),chronic relapsing polyneuropathy,CIDP,Polyradiculoneuropathy, Chronic Inflammatory Demyelinating,Chronic inflammatory demyelinating polyradiculoneuropathy

Group 0 name Corresponds to the control (unexposed) group for case-control studies: non-CIDP subjects

Group 1 name Corresponds to the case (exposed) group for case-control studies: CIDP subjects

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group: Chronic Inflammatory Demyelinating Polyneuropathy is a rare autoimmune disorder that affects the peripheral nerves. These are the nerves that carry signals from the brain and spinal cord to the muscles throughout the body. This damage disrupts the transmission of signals, which can cause weakness, numbness, pain, and fatigue.

Group 0 sample size Number of subjects in the control (unexposed) group: 33

Group 1 sample size Number of subjects in the case (exposed) group: 31

Lab analysis

Sequencing type: 16S

16S variable region One or more hypervariable region(s) of the bacterial 16S gene: Not specified

Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance: DNBSEQ-T7

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).: relative abundances

Statistical test: T-Test

Significance threshold p-value or FDR threshold used for differential abundance testing (if any): 0.05

MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?: No

Matched on Factors on which subjects have been matched on in a case-control study: type I diabetes mellitus, type II diabetes mellitus, Matched on: "dyslipidemia" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.dyslipidemia, non-alcoholic fatty liver disease, Matched on: "neurodegenerative disorders" is not in the list (abnormal glucose tolerance, acetaldehyde, acute graft vs. host disease, acute lymphoblastic leukemia, acute myeloid leukemia, adenoma, age, AIDS, alcohol consumption measurement, alcohol drinking, ...) of allowed values.neurodegenerative disorders